EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial

Jorge Sánchez, Elizabeth García, Juan-Felipe Lopez, Ana Calle, Jefferson-Antonio Buendia

The Journal of Allergy and Clinical Immunology: In Practice · 2023-07 · 11 (7) · 2172-2179

DOI: 10.1016/j.jaip.2023.04.033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-07. Verfasst von Jorge Sánchez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hospital "Alma Mater de Antioquia, " Group of Clinical and Experimental Allergy (GACE), University of Antioquia, Medellín, Colombia. Electronic addre…. Hauptthemen laut MEDLINE: Asthma, Respiration Disorders. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are no prospective studies comparing how biological therapies affect nonsteroidal anti-inflammatory drug (NSAID) tolerance in NSAID-exacerbated respiratory disease. OBJECTIVE: To study the induction of NSAID tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease. METHODS: A prospective pilot study in a real-world clinic setting was conducted among subjects with severe asthma and type 2 inflammation. A random allocation of therapy was carried out: benralizumab, dupilumab, mepolizumab, or omalizumab. NSAID intolerance was confirmed by an oral challenge test (OCT) using acetyl-salicylic acid (ASA-OCT). The principal outcome was NSAID tolerance according to OCT before and after 6 months of each biological therapy (intragroup comparisons). As exploratory outcomes, we compared NSAID tolerance between biological therapies (intergroup comparisons). RESULTS: A total of 38 subjects were included; 9 received benralizumab, 10 dupilumab, 9 mepolizumab, and 10 omalizumab. There was an increase in the concentration needed to produce a reaction during ASA-OCT with omalizumab (P < .001) and dupilumab (P = .004) but not with mepolizumab and benralizumab. Omalizumab and dupilumab achieved the highest frequency of NSAID tolerance (omalizumab 60%, dupilumab 40%, mepolizumab 22%, and benralizumab 22%). CONCLUSIONS: Biological therapies for asthma are useful for inducing NSAID tolerance; however, in patients with type 2 inflammation and high levels of total IgE, atopy, and eosinophils, anti-IgE or anti-IL4/13 seem to be more effective than antieosinophilic therapies. Omalizumab and dupilumab increased ASA tolerance, whereas mepolizumab and benralizumab did not. Future trials will be able to clarify this finding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaRespiration DisordersHumansOmalizumabPilot ProjectsAnti-Inflammatory Agents, Non-SteroidalAspirinBiological TherapyInflammation

Stichwörter der Autor:innen

Acetylsalicylic acidAspirinBenralizumabDupilumabMepolizumabNonsteroidal anti-inflammatory drug–exacerbated respiratory diseaseOmalizumabRhinosinusitisSamter’s triad

Substanzen

OmalizumabAnti-Inflammatory Agents, Non-SteroidalAspirin

Autor:innen und Institutionen

  • Hospital "Alma Mater de Antioquia, " Group of Clinical and Experimental Allergy (GACE), University of Antioquia, Medellín, Colombia. Electronic address: jorgem.sanchez@udea.edu.co.
  • Surgical Medical Unit of Otorhinolaryngology (UNIMEQ-ORL), Bogotá, Colombia.
  • Hospital "Alma Mater de Antioquia, " Group of Clinical and Experimental Allergy (GACE), University of Antioquia, Medellín, Colombia.
  • Department of Pharmacology and Toxicology, School of Medicine, Research Group in Pharmacology and Toxicology (INFARTO), University of Antioquia, Medellín, Colombia.

Zitieren

APA

Sánchez, J., García, E., Lopez, J. F., Calle, A., & Buendia, J. A. (2023). Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial. The Journal of Allergy and Clinical Immunology: In Practice, 11(7), 2172-2179. https://doi.org/10.1016/j.jaip.2023.04.033

Vancouver

Sánchez J, García E, Lopez JF, Calle A, Buendia JA. Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(7):2172-2179. doi:10.1016/j.jaip.2023.04.033

BibTeX
@article{Snchez2023,
  author = {Sánchez, Jorge and García, Elizabeth and Lopez, Juan-Felipe and Calle, Ana and Buendia, Jefferson-Antonio},
  title = {Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {7},
  pages = {2172--2179},
  doi = {10.1016/j.jaip.2023.04.033}
}
Kostenlos starten →